Can-Fite BioPharma (NYSE:CANF) Upgraded to Hold at Zacks Research

Zacks Research upgraded shares of Can-Fite BioPharma (NYSE:CANF) to a hold rating in a report issued on Wednesday,Zacks.com reports.

Other equities research analysts have also issued reports about the stock. D. Boral Capital raised shares of Can-Fite BioPharma from a “hold” rating to a “buy” rating in a report on Wednesday. HC Wainwright set a $5.00 price target on shares of Can-Fite BioPharma and gave the company a “buy” rating in a report on Tuesday. Two equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, Can-Fite BioPharma has an average rating of “Moderate Buy” and a consensus target price of $42.50.

Can-Fite BioPharma Trading Down 4.1%

Shares of Can-Fite BioPharma stock opened at $3.49 on Wednesday. Can-Fite BioPharma has a 12-month low of $2.83 and a 12-month high of $23.40. The firm has a market capitalization of $2.29 million, a price-to-earnings ratio of -1.95 and a beta of 1.09. The firm’s 50 day simple moving average is $3.36 and its two-hundred day simple moving average is $4.75.

Institutional Trading of Can-Fite BioPharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CANF. Rhumbline Advisers grew its position in Can-Fite BioPharma by 42.4% during the first quarter. Rhumbline Advisers now owns 38,268 shares of the company’s stock valued at $57,000 after buying an additional 11,388 shares during the period. Sabby Management LLC grew its position in Can-Fite BioPharma by 80.3% during the third quarter. Sabby Management LLC now owns 1,406,050 shares of the company’s stock valued at $871,000 after buying an additional 626,306 shares during the period. Finally, Jane Street Group LLC acquired a new stake in Can-Fite BioPharma during the fourth quarter valued at $41,000. Institutional investors and hedge funds own 21.00% of the company’s stock.

About Can-Fite BioPharma

Can-Fite BioPharma Ltd. is a clinical-stage biopharmaceutical company headquartered in Petah Tikva, Israel, that focuses on the development of small molecule drugs for the treatment of inflammatory, oncology and liver diseases. Established in 1994, the company leverages its proprietary technology platform centered on modulating the adenosine receptor system to advance novel therapeutic candidates. Can-Fite’s research and development efforts are directed toward addressing significant unmet medical needs in autoimmune and cancer indications.

The company’s lead product candidates include piclidenoson (CF101) and namodenoson (CF102).